Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439568 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01439568 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 90 participants.
The verdict
NCT01439568, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG LY2510924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439568
The ClinicalTrials.gov registry entry for NCT01439568 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01439568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439568 about?
NCT01439568 is a clinical study titled "A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma". The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)
What is the current status of trial NCT01439568?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2011-09. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01439568?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), LY2510924 (DRUG).
Who is sponsoring clinical trial NCT01439568?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.